Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2197 studies found for:    myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
2 Active, not recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
3 Unknown  Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
4 Recruiting Role of Osteocytes in Myeloma Bone Disease
Condition: Multiple Myeloma
Intervention:
5 Completed Oligosecretary Myeloma: Prevalence and Its Clinical Significance
Condition: Multiple Myeloma
Intervention: Other: oligosecretary
6 Completed Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
7 Completed High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: High-Dose Sequential Chemotherapy followed by ASCT
8 Withdrawn A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Dexamethasone
9 Active, not recruiting Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen;   Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen;   Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen;   Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen;   Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen;   Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen;   Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance;   Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance;   Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
10 Completed Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine
Condition: Multiple Myeloma
Intervention: Procedure: kyphoplasty
11 Completed Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
12 Terminated
Has Results
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
13 Terminated Efficacy Study of CYT997 in Multiple Myeloma
Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: CYT997
14 Terminated Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research
Condition: Multiple Myeloma
Intervention:
15 Active, not recruiting A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
Condition: Multiple Myeloma
Intervention: Other: Anti-myeloma treatment at physician discretion
16 Completed Therapeutic Research in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Other: No drugs are involved
17 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
18 Recruiting Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Condition: Myeloma
Intervention: Drug: DS-3032b
19 Completed Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: zoledronic acid
20 Completed A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.